RetatrutideIllustrative mockup✱ Metabolic Research · Weight Management
Retatrutide
An investigational triple-receptor agonist acting on GIP, GLP-1 and glucagon receptors.
Code
RT10
Per vial
$179.00
Kit (10 vials)
$1,790.00
Quote and order requests are disabled for this listing because it has no lawful consumer treatment pathway.
Investigational compound · not FDA-approved. Retatrutide is an investigational drug in clinical trials. It is not FDA-approved and is not legally available for consumer use outside of trials. Educational information only — no purchase, quote or prescription requests.
✱ Overview
What is Retatrutide?
Retatrutide is an investigational once-weekly injectable medicine under development for obesity and related conditions. It acts on three hormone receptors: GIP, GLP-1 and glucagon.
Phase 2 results published in 2023 drew wide attention; phase 3 trials are ongoing. Until regulators review the full evidence, it remains investigational.
✱ Mechanism
How it works
GLP-1 and GIP receptor activation signals fullness to the brain, slows stomach emptying and enhances glucose-dependent insulin release.
Glucagon receptor activation is thought to increase energy expenditure and liver fat processing. Combining all three is the hypothesis being tested in trials.
✱ Key research areas
What the science says — and how sure it is.
01
Appetite regulation
Preliminary findings
Phase 2 data showed large reductions in body weight over 48 weeks in a controlled trial.
02
Glucose regulation
Preliminary findings
HbA1c improvements were observed in people with type 2 diabetes in phase 2.
03
Energy expenditure
Experimental hypothesis
The glucagon component is proposed to raise energy use; human confirmation is ongoing.
04
Clinical trial research
Preliminary findings
Phase 3 trials are evaluating efficacy and long-term safety.
✱ Available specifications
Catalog reference
| Code | Specification | Vials / kit | Ref. price / vial | Kit total (calc.) |
|---|---|---|---|---|
| RT10 | 10 mg/vial | 10 | $179.00 | $1,790.00 |
Prices are editable, illustrative per-vial references — not verified supplier costs or selling prices. Kit total = per-vial price × vials per kit. For this listing, prices are internal catalog references only, not consumer offers.
✱ Inquiry process
What happens next
01
Learn
Read the science and regulatory status above.
02
Ask
Send a general research-information inquiry.
03
Talk to a clinician
Ask a licensed professional about approved alternatives or clinical trials.
✱ Evidence & safety
Read before you ask.
Evidence quality: Promising but incomplete — phase 3 results and regulatory review pending.
Regulatory status: Investigational compound · not FDA-approved
Known safety concerns
- Nausea, vomiting, diarrhea and constipation
- Increased heart rate observed in trials
- Unknown long-term safety
- Products sold online outside trials may be counterfeit or contaminated
Contraindications & cautions
- Not available outside clinical trials
- Personal or family history of medullary thyroid carcinoma (class concern for incretin agonists)
This information is educational and incomplete. Always seek advice from a qualified medical professional.
✱ FAQ
Retatrutide questions
No. It is investigational and not legally available for consumer use. Ask your clinician about approved options or clinical trials.
Tirzepatide acts on GIP and GLP-1 receptors; retatrutide adds the glucagon receptor.
ClinicalTrials.gov lists active studies.
✱ Research information
Have a question about Retatrutide?
This is a general information inquiry. It does not request purchase, treatment or a prescription.
✱ Related
You may also want to read about
Lipo-C + B12✱ Metabolic Health
Lipo-C + B12
A lipotropic and vitamin B12 formulation explored for its role in fat metabolism and cellular energy pathways.
Tirzepatide✱ Metabolic Health
Tirzepatide
A dual GIP and GLP-1 receptor agonist used in FDA-approved prescription medicines for specific indications.